Monopar Therapeutics (MNPR) Other Non-Current Assets (2016 - 2021)

Monopar Therapeutics has reported Other Non-Current Assets for 6 years, with the latest figure at $68858.0 in Q3 2021.

• Quarterly Other Non-Current Assets changed 0.0% year-over-year to $68858.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $68858.0 (changed 0.0% YoY) and the FY2020 annual result came in at $68858.0, down 43.73% from the prior year.
• Other Non-Current Assets was little changed at $68858.0 in Q3 2021 per MNPR's latest filing, from $68858.0 in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $800031.0 in Q4 2017 and troughed at $65731.0 in Q4 2018.
• A 5-year average of $260660.5 and a median of $70954.0 in 2020 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2018 and 2019: Other Non-Current Assets plunged 91.78% in 2018, then jumped 86.18% in 2019.
• Over 5 years, Other Non-Current Assets stood at $800031.0 in 2017, then slumped by 91.78% to $65731.0 in 2018, then surged by 86.18% to $122381.0 in 2019, then plunged by 43.73% to $68858.0 in 2020, then changed by 0.0% to $68858.0 in 2021.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $68858.0, $68858.0, and $68858.0 for Q3 2021, Q2 2021, and Q1 2021 respectively.